SMS Pharmaceuticals has announced that its Unit VII manufacturing facility in Visakhapatnam, Andhra Pradesh, has received prequalification approval from the World Health Organisation (WHO) Geneva.

This significant milestone enhances the company’s global regulatory standing and enables it to increase its presence in the global market for Anti-Retroviral (ARV) APIs.

Commenting on this achievement, P. Vamsi Krishna, Executive Director, SMS Pharmaceuticals stated, “The WHO Geneva prequalification reflects the company's strong compliance with stringent international regulatory standards, reinforcing its reputation for quality, reliability, and global competitiveness.”

Established in 1990, SMS Pharmaceuticals is a diversified and integrated pharmaceutical company specialising in API and intermediates for global customers. The company operates two state-of-the-art manufacturing facilities in Hyderabad and Vizag, with capacities of 120 KL and 3,000 KL, respectively.